Breaking News Instant updates and real-time market news.

BIIB

Biogen

$318.11

-0.21 (-0.07%)

, LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

08:05
11/23/16
11/23
08:05
11/23/16
08:05

Piper's Schimmer proclaims amyloid hypothesis is not dead

Piper Jaffray analyst Joshua Schimmer says the failure of Eli Lilly's (LLY) solanezumab is not the final nail in the amyloid hypothesis coffin. Biogen (BIIB) and Eisai's aducanimab study is the most potent approach for amyloid lowering, Schimmer tells investors in a research note. He points out that he was skeptical whether solanezumab's effect was adequate. "Our view of Alzheimer's for amyloid is informed not so much by the extremely sloppy science in that disease, but by consistent cause/effect signals across other amyloidosis," Schimmer writes. He believes today's selloff in shares of Biogen "creates some breathing room." The analyst recommends looking to build a position in Biogen after the stock settles down. Schimmer reiterates an Overweight rating on the shares with a $335 price target. The stock is down 8%, or $24.41, to $293.70 in pre-market trading.

BIIB

Biogen

$318.11

-0.21 (-0.07%)

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

  • 29

    Nov

  • 04

    Dec

BIIB Biogen
$318.11

-0.21 (-0.07%)

11/08/16
11/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adient (ADNT) initiated with a Neutral at JPMorgan. 2. JinkoSolar (JKS) initiated with a Buy at Craig-Hallum. 3. Amgen (AMGN), Gilead (GILD), and Celgene (CELG) initiated with a Buy at Mizuho while the firm initiated Biogen (BIIB) with a Neutral. 4. BioScrip (BIOS) resumed with a Buy at Jefferies. 5. SQM (SQM) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Neutral
Citi pegs potential Biogen downside to $287 on Lilly failure
In a research note dated yesterday, Citi analyst Robyn Karnauskas said shares of Biogen (BIIB) could fall to $286 should Eli Lilly's (LLY) Alzheimer's drug solanezumab fail in its Phase 3 study. After Lilly reported this morning that the trial failed, shares of Biogen are down 6%, or $18.60, to $299.51 in pre-market trading. Shares of Lilly are down 14%, or $10.77, to $65.22. Karnauskas estimated the downside range of Biogen on a failed solanezumab study at $287-$306. The analyst has a Neutral rating on Biogen.
LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.

TODAY'S FREE FLY STORIES

CRM

Salesforce

$86.00

-2.09 (-2.37%)

11:55
06/29/17
06/29
11:55
06/29/17
11:55
Options
Salesforce put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
06/29/17
06/29
11:55
06/29/17
11:55
General news
Treasury Action: the long end of the curve remains weaker »

Treasury Action: the long…

NFX

Newfield Exploration

$28.45

0.89 (3.23%)

11:45
06/29/17
06/29
11:45
06/29/17
11:45
Options
Newfield Exploration call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

XLK

Technology Select Sector SPDR

$54.81

-0.96 (-1.72%)

, XLF

Financial Select Sector

$24.79

0.27 (1.10%)

11:38
06/29/17
06/29
11:38
06/29/17
11:38
Technical Analysis
Technical View: S&P 500 breaks 2420, bounces fractionally »

The S&P 500 (SPX)…

XLK

Technology Select Sector SPDR

$54.81

-0.96 (-1.72%)

XLF

Financial Select Sector

$24.79

0.27 (1.10%)

SPY

SPDR S&P 500 ETF Trust

$241.95

-1.54 (-0.63%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$91.56

1.7362 (1.93%)

11:30
06/29/17
06/29
11:30
06/29/17
11:30
Options
Bullish option play in JP Morgan as shares rally »

Bullish option play in JP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jul

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

11:25
06/29/17
06/29
11:25
06/29/17
11:25
General news
Treasury announced a $72 B 3- and 6-month bill auction for Monday »

Treasury announced a $72…

INFO

IHS Markit

$45.05

-0.32 (-0.71%)

11:25
06/29/17
06/29
11:25
06/29/17
11:25
Conference/Events
The National Economists Club to hold a luncheon meeting Symbol changed to INFO IHS Markit »

National Economists Club…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

QVCA

QVC Group

$24.61

0.1 (0.41%)

, QVCB

QVC Group

11:25
06/29/17
06/29
11:25
06/29/17
11:25
Conference/Events
FBN Securities media analyst to hold a luncheon meeting »

Media Analyst Routh…

QVCA

QVC Group

$24.61

0.1 (0.41%)

QVCB

QVC Group

LVNTA

Liberty Ventures

$52.69

1.21 (2.35%)

GNCMA

General Communications

$36.81

0.97 (2.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 10

    Jul

ALRN

Aileron Therapeutics

11:23
06/29/17
06/29
11:23
06/29/17
11:23
Syndicate
Breaking Syndicate news story on Aileron Therapeutics »

Aileron Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

SHLD

Sears

$8.01

0.29 (3.76%)

11:22
06/29/17
06/29
11:22
06/29/17
11:22
Hot Stocks
Breaking Hot Stocks news story on Sears »

Returning to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$8.01

0.29 (3.76%)

11:20
06/29/17
06/29
11:20
06/29/17
11:20
Hot Stocks
Breaking Hot Stocks news story on Sears »

Berkowitz says Fairholme…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$72.91

-0.01 (-0.01%)

11:20
06/29/17
06/29
11:20
06/29/17
11:20
Options
Abbvie attracts an opening call write »

Abbvie attracts an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$8.01

0.29 (3.76%)

11:17
06/29/17
06/29
11:17
06/29/17
11:17
Hot Stocks
Real estate value the 'margin of safety' in Sears investment, Berkowitz says »

Bruce Berkowitz,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
06/29/17
06/29
11:17
06/29/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$8.01

0.29 (3.76%)

11:16
06/29/17
06/29
11:16
06/29/17
11:16
Hot Stocks
Berkowitz sees Sears net asset value at $90 per share »

Bruce Berkowitz of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
06/29/17
06/29
11:16
06/29/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOGL

Alphabet Class A

$961.01

12.92 (1.36%)

11:14
06/29/17
06/29
11:14
06/29/17
11:14
Technical Analysis
Technical View: Alphabet Class A has an active bearish pattern »

A bearish head and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

$1.87

0.039 (2.13%)

11:13
06/29/17
06/29
11:13
06/29/17
11:13
Hot Stocks
Bombardier says Transportation restructuring costs included in previous guidance »

As part of the global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:11
06/29/17
06/29
11:11
06/29/17
11:11
General news
4-Week Bill Announcement Offering Amount data reported »

4-Week Bill Announcement…

11:11
06/29/17
06/29
11:11
06/29/17
11:11
General news
6-Month Bill Announcement Offering Amount data reported »

6-Month Bill Announcement…

11:11
06/29/17
06/29
11:11
06/29/17
11:11
General news
3-Month Bill Announcement Offering Amount data reported »

3-Month Bill Announcement…

DBD

Diebold

$27.88

0.425 (1.55%)

11:11
06/29/17
06/29
11:11
06/29/17
11:11
Hot Stocks
CMA says Diebold sale resolves concerns over cashpoint merger »

After the Competition and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHTR

Charter

$340.30

10.43 (3.16%)

11:10
06/29/17
06/29
11:10
06/29/17
11:10
Options
Renewed call buying in Charter »

Renewed call buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

JCOM

j2 Global

$87.08

0.83 (0.96%)

, TWTR

Twitter

$17.74

-0.2132 (-1.19%)

11:06
06/29/17
06/29
11:06
06/29/17
11:06
Hot Stocks
IGN, Twitter partner for global live stream of San Diego Comic-Con »

J2 Global's (JCOM)…

JCOM

j2 Global

$87.08

0.83 (0.96%)

TWTR

Twitter

$17.74

-0.2132 (-1.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 28

    Sep

CY

Cypress Semiconductor

$14.35

1.15 (8.71%)

, ARW

Arrow Electronics

$79.00

-0.48 (-0.60%)

11:02
06/29/17
06/29
11:02
06/29/17
11:02
Hot Stocks
Cypress Semiconductor, Arrow Electronics announce IoT development platform »

Cypress Semiconductor…

CY

Cypress Semiconductor

$14.35

1.15 (8.71%)

ARW

Arrow Electronics

$79.00

-0.48 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 07

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.